Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 1/20 | 0.43 |
| ▸ | PTPRO | Q16827 | 1/20 | 0.43 |
| ▸ | STAT3 | P40763 | 4/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | LTB4R2 | Q9NPC1 | 6/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | MMP9 | P14780 | 1/20 | 0.35 |
| ▸ | TSPO | P30536 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13711748 | 0.92 | STAT3 (0.40) | STAT3POLBLTB4R2 | |
| SCHEMBL2861548 | 0.90 | PTPN11 (0.41) | PTPN11PTPROSTAT3LTB4R2 | |
| SCHEMBL2851643 | 0.90 | PTPN11 (0.40) | PTPN11PTPROSTAT3POLBLTB4R2 | |
| SCHEMBL2856906 | 0.89 | PTPN11 (0.39) | PTPN11PTPROSTAT3POLBLTB4R2 | |
| SCHEMBL2852877 | 0.86 | CNR2 (0.42) | PTPN11PTPRO | |
| SCHEMBL2855107 | 0.84 | PTPN11 (0.36) | PTPN11PTPROPOLBLTB4R2 | |
| SCHEMBL13513494 | 0.84 | PTPN11 (0.37) | PTPN11PTPROSTAT3POLBMMP2 | |
| SCHEMBL13711707 | 0.84 | PTPN11 (0.39) | PTPN11PTPROSTAT3POLBLTB4R2 | |
| SCHEMBL1811360 | 0.83 | PTPN11 (0.56) | PTPN11PTPROPOLB | |
| SCHEMBL2848860 | 0.83 | PTPN11 (0.41) | PTPN11PTPROSTAT3LTB4R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1654247-B1 | ALKYNYL ARYL CARBOXAMIDES | MERCK SERONO SA (CH) | 2010-01-20 | — | — | EP | disclosed |
| EP-1654247-B1 | ALKYNYL ARYL CARBOXAMIDES | MERCK SERONO SA (CH) | 2010-01-20 | — | — | EP | disclosed |
| US-7589232-B2 | Alkynyl aryl carboxamides | LABORATORIES SERONO S.A. (CH) | 2009-09-15 | — | — | US | disclosed |
| US-7589232-B2 | Alkynyl aryl carboxamides | LABORATORIES SERONO S.A. (CH) | 2009-09-15 | — | — | US | disclosed |
| US-20070105913-A1 | Alkynyl aryl carboxamides | APPLIED RESEARCH SYSTEMS ARS HOLDINGS N.V. (NL) | 2007-05-10 | — | — | US | disclosed |
| US-20070105913-A1 | Alkynyl aryl carboxamides | APPLIED RESEARCH SYSTEMS ARS HOLDINGS N.V. (NL) | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105913-A1 | Alkynyl aryl carboxamides | ECHS1, IRS1, HCCS | PTPN11 97/4885PTPRO 51/4885STAT3 2684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.